ID30255A - Metoda untuk mencegah atau menunda revaskularisasi berdasarkan kateter - Google Patents

Metoda untuk mencegah atau menunda revaskularisasi berdasarkan kateter

Info

Publication number
ID30255A
ID30255A IDW20010902A ID20010902A ID30255A ID 30255 A ID30255 A ID 30255A ID W20010902 A IDW20010902 A ID W20010902A ID 20010902 A ID20010902 A ID 20010902A ID 30255 A ID30255 A ID 30255A
Authority
ID
Indonesia
Prior art keywords
caterater
delaying
preventing
methods
revascularization
Prior art date
Application number
IDW20010902A
Other languages
English (en)
Indonesian (id)
Inventor
Donald Michael Black
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID30255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID30255A publication Critical patent/ID30255A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
IDW20010902A 1998-09-30 1999-07-08 Metoda untuk mencegah atau menunda revaskularisasi berdasarkan kateter ID30255A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
ID30255A true ID30255A (id) 2001-11-15

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010902A ID30255A (id) 1998-09-30 1999-07-08 Metoda untuk mencegah atau menunda revaskularisasi berdasarkan kateter

Country Status (34)

Country Link
US (1) US20080119561A1 (de)
EP (1) EP1117392B1 (de)
JP (1) JP2002525321A (de)
KR (1) KR20010079955A (de)
CN (1) CN1197565C (de)
AP (1) AP1708A (de)
AT (1) ATE260100T1 (de)
AU (1) AU768474B2 (de)
BG (1) BG105471A (de)
BR (1) BR9914098A (de)
CA (1) CA2343299C (de)
CZ (1) CZ20011035A3 (de)
DE (1) DE69915084T2 (de)
DK (1) DK1117392T3 (de)
EA (1) EA007427B1 (de)
EE (1) EE200100199A (de)
ES (1) ES2214872T3 (de)
HR (1) HRP20010236A2 (de)
HU (1) HUP0103648A3 (de)
ID (1) ID30255A (de)
IL (2) IL141953A0 (de)
IS (1) IS5889A (de)
NO (1) NO20011615L (de)
NZ (1) NZ510500A (de)
OA (1) OA11787A (de)
PL (1) PL346980A1 (de)
PT (1) PT1117392E (de)
SI (1) SI1117392T1 (de)
SK (1) SK4122001A3 (de)
TR (1) TR200100901T2 (de)
UA (1) UA73292C2 (de)
WO (1) WO2000018395A1 (de)
YU (1) YU23901A (de)
ZA (1) ZA200102230B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
CA2414783A1 (en) * 2000-07-14 2002-01-24 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5957916A (en) * 1994-05-25 1999-09-28 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CZ127198A3 (cs) * 1995-11-02 1998-12-16 Warner-Lambert Company Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
AU4228997A (en) * 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
HK1042436A1 (en) 2002-08-16
CA2343299C (en) 2008-04-01
YU23901A (sh) 2003-07-07
AP2001002112A0 (en) 2001-06-30
EP1117392B1 (de) 2004-02-25
NZ510500A (en) 2003-10-31
HUP0103648A2 (hu) 2003-08-28
CN1342072A (zh) 2002-03-27
DE69915084D1 (de) 2004-04-01
EP1117392A1 (de) 2001-07-25
ATE260100T1 (de) 2004-03-15
CA2343299A1 (en) 2000-04-06
EA007427B1 (ru) 2006-10-27
SI1117392T1 (en) 2004-06-30
EE200100199A (et) 2002-06-17
UA73292C2 (en) 2005-07-15
NO20011615D0 (no) 2001-03-29
PL346980A1 (en) 2002-03-11
PT1117392E (pt) 2004-07-30
CN1197565C (zh) 2005-04-20
BG105471A (bg) 2001-12-31
EA200100370A1 (ru) 2001-10-22
ZA200102230B (en) 2002-06-18
DK1117392T3 (da) 2004-06-14
ES2214872T3 (es) 2004-09-16
TR200100901T2 (tr) 2001-08-21
US20080119561A1 (en) 2008-05-22
WO2000018395A1 (en) 2000-04-06
IL141953A0 (en) 2002-03-10
AU768474B2 (en) 2003-12-11
HUP0103648A3 (en) 2003-10-28
IS5889A (is) 2001-03-14
HRP20010236A2 (en) 2002-04-30
AU4975099A (en) 2000-04-17
AP1708A (en) 2007-01-10
OA11787A (en) 2005-07-26
SK4122001A3 (en) 2002-06-04
JP2002525321A (ja) 2002-08-13
NO20011615L (no) 2001-04-24
CZ20011035A3 (cs) 2001-10-17
KR20010079955A (ko) 2001-08-22
BR9914098A (pt) 2001-07-31
DE69915084T2 (de) 2004-07-22
IL141953A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
DE69938817D1 (de) Erstellungsverfahren
FI981491L (fi) Tukiaseman konfigurointimenetelmä
DE69916360D1 (de) Flügelprofil
TR199900531A3 (tr) Pirazolopirimidinler ve pirazolotriazinler.
DE69943006D1 (de) Kühlkörper
DE69908200D1 (de) Korkenzieher
EE200100199A (et) Kateetrilpõhineva revaskularisatsiooni ennetamisevõi edasilükkamise meetod
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID28624A (id) Turunan 2-fenilpiran-4-on
DE69904933D1 (de) Verriegelungsvorrichtung
DE59900726D1 (de) Verriegelungsvorrichtung
ID23196A (id) Gandaran untuk lampuflouresen
FR2777750B1 (fr) Assaisonnement
DE69810450D1 (de) Verriegelungsvorrichtung
DE59906422D1 (de) Stellvorrichtung
DE69818799D1 (de) Verriegelungsvorrichtung
DE69930852D1 (de) Prenyltransferase-inhibitoren
DE69909568D1 (de) Verriegelungsvorrichtung
NO994785L (no) Kabellås
FI981207L (fi) Demodulaatiomenetelmä
ES1039265Y (es) Rocodromo perfeccionado.
FI3582U1 (fi) Vääntölaite
SE9804251D0 (sv) Låskomponent
SE9804356D0 (sv) Spärranordning
FI980851L (fi) Lukitusväline